[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stroke-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stroke-acute":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,87,0,25,[9,47,77,101,128,150,176,205,237,274,294,321,342,370,389,412,432,459,481,506,530,558,584,605,626],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100552185","ecmo-abi-detection-with-hyperfine-100552185",false,"NCT06469801","ECMO ABI Detection With Hyperfine","Low-Field Bedside MRI for Detection of Acute Brain Injury in Pediatric Extracorporeal Membrane Oxygenation","Inclusion Criteria\n\n* Participants that will be or are admitted to the Pediatric Intensive Care Unit, Cardiac Intensive Care Unit, or the Neonatal Intensive Care Unit\n* Ages 0-17 years\n* Participants that are at high risk for undergoing ECMO or are currently undergoing venovenous or venoarterial ECMO\n\n  • High risk participants include, but are not limited to:\n* Undergoing cardiac surgery\n* Congenital heart disease\n* Congenital diaphragmatic hernia\n* Refractory hypoxemic and\u002For hypercarbic respiratory failure\n* Vasoactive-refractory shock\n\nExclusion Criteria\n\n* Pregnancy\n* Active implants such as:\n\n  * Pacemaker\n  * Implanted defibrillator\n  * Implanted insulin pump\n  * Deep brain stimulator\n  * Vagus nerve stimulator\n  * Cochlear implant\n  * Programmable shunt\n* MRI incompatible surgical hardware (e.g., staples, screws, etc.)\n* Metal-containing tattoos or permanent make-up on head or neck\n* Suspected metal in eye, e.g.,\n* Former or current welders, metal workers, or individuals with a metal injury\n* Metal shrapnel\n* Passive implants are considered MRI-conditional","ALL","0 Days","17 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","The primary objective is to characterize the prevalence and type of ABI following cannulation for pediatric patients who require ECMO support. The secondary objective is to describe the time course and rates of ABI using ultralow-field bedside MRI relative to both duration of ECMO support and clinical imaging obtained in routine care of pediatric ECMO patients.",[28,29,30,31],"Acute Brain Injury","Extracorporeal Membrane Oxygenation Complication","Hypoxia-Ischemia, Brain","Stroke, Acute",[33],"Pediatric","RECRUITING","2026-06-30",{"date":37,"type":38},"2026-07-01","ACTUAL",{"date":40,"type":38},"2024-07-23",{"date":42,"type":22},"2027-12-01",{"name":44,"class":45},"Children's Mercy Hospital Kansas City","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100540311","stroke-alarm-efficacy-trial-100540311","NCT06315192","Stroke Alarm Efficacy Trial","StrokeAlarmEFF","INCLUSION CRITERIA\n\n1. Age 50 years or older\n2. Modified Rankin scale of 0-2.\n3. Diagnosed with either:\n\n   A. Recent\\* transient ischemic attack (TIA, G45.9), AND:\n   * ABCD2 score of ≥6, OR:\n   * Atrial fibrillation OR:\n   * Large artery atherosclerosis\\*\\*.\n\n   B. Recent\\* acute ischemic stroke (I63), AND:\n\n   • Atrial fibrillation, OR:\n   * Large artery atherosclerosis\\*\\*. C. Atrial fibrillation\u002Fflutter (I48), AND\n   * None, or reduced dose of, oral anticoagulation medication\\*\\*\\*, AND\n   * CHA2DS2-VASC score ≥4.\n\n   D. Recent\\* intracerebral hemorrhage (I61.9), AND:\n\n   • Atrial fibrillation.\n4. The patient has received the required information about the study and agrees in writing to participate.\n5. Smartphone user since at least 1 year.\n\n   * Within the last 2 weeks \\*\\*Atherosclerosis in carotid, vertebral aortic arch or major intracerebral arteries according to CTA or ultrasound.\n\n     * Including all oral anticoagulation medication such as Warfarin and NOACs. Patients with reduced dose of a NOAC can be included, regardless if this is within the approved label, or if reduced dose is chosen off-label for other reasons. Treatment with antiplatelet medication is permissible.\n\nEXCLUSION CRITERIA\n\n1. Previous inclusion in this study.\n2. Arm motor deficit from any previous medical condition.\n3. Unable to give informed consent to participate in the study.\n4. Does not master any of the languages available within the Stroke Alarm smartphone app in speech and writing.\n5. Does not have access to a Stroke Alarm compatible smartphone.\n6. Deemed unable to handle the Stroke Alarm smartphone app, or participate in planned follow-up within the framework of the study due to other diseases or circumstances.\n7. Does not want to participate.","18 Years",{"count":56,"type":22},500,[25],"The aim of this study is to test the efficacy of the CE-marked wearable system Stroke Alarm to identify the onset of a stroke with unilateral arm motor deficit within 3 hours of onset.\n\nThis is a multicenter, prospective observational single-arm trial with a registry-based propensity matched control population.\n\nA total of 500 patients will be included in the trial. An interim analysis will determine if the stroke onset frequency is sufficient to determine the main outcome. Should the number of stroke events differ from what is expected at interim analysis, study enrollment will continue to increase cohort size.\n\nPatients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.\n\nPatients with elevated stroke risk according assessed by presence of specific criteria associated with elevated risk caused by:\n\n1. recent TIA with an ABCD2 score of ≥6, large artery atherosclerosis or atrial fibrillation, OR\n2. recent ischemic stroke with large artery atherosclerosis or atrial fibrillation, without persisting arm motor deficit, OR\n3. atrial fibrillation with an CHA2DS2-Vasc score ≥ 4 without adequate anticoagulation OR\n4. recent hemorrhagic stroke with atrial fibrillation, without persisting arm motor deficit The combined efficacy goal is at least 60% sensitivity for Stroke Alarm b of stroke with unilateral arm motor deficit within 3 hours of onset (with a 95% confidence interval above 30%) and a specificity of at least 80% using a clinical stroke diagnosis as gold standard.\n\nA control population matched for calendar year, age (± 5 years), sex, healthcare region, baseline stroke severity according to the National Institutes of Health Stroke Scale (NIHSS, ± 5 points), unilateral arm motor deficit (NIHSS item 5a\u002F5b 1-4), presence of neglect\u002Finattention (NIHSS item 11 1-2), atrial fibrillation, cohabitation status and pre-stroke functional level twill be identified in the Swedish national stroke registry, Riksstroke, and used for comparison.",[60,61,62],"Stroke Acute","Atrial Fibrillation","TIA",[64,65,66,67],"Stroke","wearable","indication","sensor","2026-06-29",{"date":35,"type":38},{"date":71,"type":38},"2024-09-05",{"date":73,"type":22},"2027-12-31",{"name":75,"class":45},"Region Skane",10,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":46},"100622097","phase-3-hr-mri-directed-tirofiban-therapy-for-late-window-acute-ischemic-stroke-tian-100622097","NCT07379190","HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)","Efficacy and Safety of Tirofiban Therapy in Acute Ischemic Stroke Patients Beyond the Time Window Guided by High-Resolution Magnetic Resonance Imaging","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Acute ischemic stroke (AIS) in the anterior intracranial circulation (internal carotid artery system) confirmed by clinical symptoms and imaging examinations;\n3. Time from symptom onset or last known normal state to randomization: \\> 24 hours and ≤ 7 days;\n4. Stroke subtype confirmed as intracranial large artery atherosclerosis (ICAS) by high-resolution vessel wall imaging (HR-VWI) according to the TOAST classification, with cardiogenic embolism and other etiologies excluded;\n5. Baseline National Institutes of Health Stroke Scale (NIHSS) score of 4-20 at the time of randomization;\n6. Signed informed consent form obtained from the patient or their legal representative.\n\nExclusion Criteria:\n\n1. Planned to receive reperfusion therapy (endovascular therapy or intravenous thrombolysis)；\n2. Intracranial hemorrhage confirmed by computed tomography (CT)；\n3. Definite or suspected cardiogenic embolism；\n4. History of atrial fibrillation or current electrocardiogram indicating atrial fibrillation；\n5. Acute ischemic stroke caused by other etiologies, such as Moyamoya disease, arterial dissection, arteritis, etc；\n6. Imaging examinations indicating that the area of the current cerebral infarction exceeds 1\u002F2 of the area of a single cerebral lobe;\n7. Known contraindications to antiplatelet therapy, including hematochezia, gastrointestinal bleeding, or any other hemorrhagic disorders;\n8. History of hypersensitivity to aspirin;\n9. Definite indication for anticoagulant therapy expected during the study period (e.g., atrial fibrillation, mechanical heart valve, deep vein thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state, etc.);\n10. Complicated with malignant tumors, chronic hemodialysis, severe renal insufficiency (glomerular filtration rate \\[GFR\\] \\\u003C 30 ml\u002Fmin or serum creatinine \\[Cr\\] \\> 220 μmol\u002FL (2.5 mg\u002Fdl)), or severe hepatic insufficiency (serum alanine aminotransferase \\[ALT\\] \\> 2 times the upper limit of normal \\[ULN\\], or serum aspartate aminotransferase \\[AST\\] \\> 2 times the ULN);\n11. Severe heart failure (New York Heart Association \\[NYHA\\] Functional Classification Class III or IV);\n12. Complicated with severe non-cardiovascular comorbidities, with an estimated survival time \\\u003C 6 months;\n13. Concurrent new cerebral infarction in both anterior and posterior circulations;\n14. Inability to complete the follow-up procedures;\n15. Presence of other known neurological disorders that may complicate the follow-up;\n16. Concurrent participation in other therapeutic clinical trials with incomplete treatment and follow-up;\n17. Other conditions that the investigators consider inappropriate for enrollment in this study.",{"count":85,"type":22},458,[87],"PHASE3","This study aims to address the existing clinical challenges by introducing high-resolution magnetic resonance vessel wall imaging (HR-MRI), an advanced imaging technology, to achieve precise etiological classification in patients with acute ischemic stroke (AIS) beyond the time window. HR-MRI allows clear visualization of intracranial arterial wall structures and direct identification of key pathological features of the culprit vessel, including atherosclerotic plaques, vascular wall remodeling, and intracranial hemorrhage, thereby enabling reliable differentiation between intracranial atherosclerotic large artery atherosclerosis (ICAS-LAA) stroke and other etiological subtypes such as cardiogenic embolism. Based on the latest clinical demands and advances in imaging technology, this study intends to evaluate the efficacy and safety of tirofiban in patients with ICAS-LAA stroke beyond the time window under the precise guidance of HR-MRI. It is expected to provide high-level evidence-based medical evidence for this specific patient population and further optimize clinical diagnosis and treatment strategies.",[31,90,91],"Stroke, Ischemic","Cerebral Infarction","2026-06-24",{"date":94,"type":38},"2026-06-25",{"date":96,"type":38},"2026-06-22",{"date":98,"type":22},"2029-05-01",{"name":100,"class":45},"Weifang Medical University",{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":17,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":46},"100612460","comperative-effects-of-transcutaneous-auricular-and-cervical-vagus-nerve-stimulation-in-subacute-stroke-patients-100612460","NCT07253870","Comperative Effects of Transcutaneous Auricular and Cervical Vagus Nerve Stimulation in Subacute Stroke Patients","Comparative Effects of Transcutaneous Auricular and Cervical Vagus Nerve Stimulation on Upper Limb Function, Cognition and Quality of Life in Subacute Stroke Patients","Inclusion Criteria:\n\n* First ever ischemic stroke\n* Subacute phase of stroke 3-6 months post onset\n* Fugl-Meyer Assessment-Upper Extremity (FMA-UE) scores ranged from 20 - 50\n\nExclusion Criteria:\n\n* Previous injury or surgical intervention of vagus nerve\n* Patients with cardiac arrest and arrythmias\n* Uncontrolled hypertension\n* Apraxia\n* Other neurologic or musculoskeletal diseases\n* Presence of implanted electronic devices","45 Years","70 Years",{"count":111,"type":22},54,[25],"This study aims to determine whether transcutaneous vagus nerve stimulation (tVNS) via auricular or cervical branches enhances recovery when combined with task-specific training in subacute stroke patients. We anticipate finding that both stimulation methods may improve upper limb motor function compared to conventional therapy. The research is expected to reveal specific cognitive domains (attention, memory, executive function) that benefit most from each stimulation approach, while also demonstrating meaningful improvements in patients' quality of life measures. These findings may make a significant practical contribution by providing clinicians with evidence-based guidance on suitable tVNS approach for improving functional independence and quality of life for stroke survivors.",[64,31],[116,117,118],"Task Specific Training","Upper Limb Function","Cognition","2026-06-17",{"date":121,"type":38},"2026-06-18",{"date":123,"type":38},"2025-11-20",{"date":125,"type":22},"2026-06-20",{"name":127,"class":45},"Lahore University of Biological and Applied Sciences",{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":46},"100624584","individual-vs-co-treatment-in-acute-stroke-rehabilitation-and-evaluation-100624584","NCT07411534","Individual vs Co-Treatment in Acute Stroke Rehabilitation and Evaluation","ICARE","Inclusion Criteria:\n\n* Inpatient admission to the neurology stroke service AND\n* Orders placed for both PT and OT within 96 hours of admission to the service\n\nExclusion Criteria:\n\n* Patient is known to be \\\u003C18 years\n* Patient is known to be a prisoner\n* Patient is known to be pregnant\n* Prior evaluation or treatment by PT and\u002For OT while admitted under the stroke service before study enrollment\n* Clinician determines that either individual PT and OT or co-treatment is required or contraindicated for the optimal care of the patient",{"count":136,"type":22},567,[25],"This is a single center, pragmatic, randomized trial comparing the effectiveness of two commonly used approaches (co-treatment and individual treatment) in acute care rehabilitation.",[64,60],"NOT_YET_RECRUITING","2026-06-08",{"date":143,"type":38},"2026-06-10",{"date":145,"type":22},"2026-09-01",{"date":147,"type":22},"2027-12-28",{"name":149,"class":45},"Vanderbilt University Medical Center",{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":46},"100639678","ivr-on-upper-limb-rehabilitation-in-stroke-patients-a-clinical-trial-100639678","NCT07609966","IVR ON UPPER-LIMB REHABILITATION IN STROKE PATIENTS: A CLINICAL TRIAL","Impact of Immersive Virtual Reality in the Rehabilitation in the Acute Phase of Stroke: a Clinical Study and Correlation With Blood Biomarkers and Polymorphisms Related to Neuroplasticity","REVICTUS","Inclusion Criteria: Diagnosis of ischemic stroke or intracerebral hemorrhage. Age \\> 18 years. \\\u003C 7 days between stroke onset and inclusion in the study. Impairment of mobility in the right or left upper limb due to stroke. After hospital discharge, patients continue an intensive conventional rehabilitation (ICR) program at their referral rehabilitation center (MUTUAM).\n\nAbility to understand and sign the study informed consent form (ICF) and the IDIBGI Biobank informed consent form.\n\n\\-\n\nExclusion Criteria:\n\nPrevious upper limb disability (neurological or non-neurological cause). Previous dementia or any disease with a life expectancy of less than 1 year. Language comprehension difficulties. Difficulty remembering exercise instructions. History of photosensitive epilepsy.\n\n\\-",{"count":159,"type":22},120,[25],"Stroke is the leading cause of acquired disability in adults. Neurorehabilitation aims to recover the affected function by stimulating neuroplasticity. Immersive virtual reality (IVR) has shown that it can be effective but the evidence is still weak. Similarly, few studies have analysed blood biomarkers as outcome or predictive indicators, and knowledge of the influence of genetic polymorphisms on rehabilitation efficacy is limited. Our objectives are (1) to demonstrate that the addition of IVR to conventional rehabilitation (CR) improves upper-limb motor function, functional status, and quality of life in stroke patients, at short and long term; (2) to determine the effect of IVR on the expression of neuroplasticity biomarkers at long term; (3) to evaluate the impact of genetic polymorphisms on the rehabilitation and functional prognosis of treated patients, at short and long term; and (4) to identify acute phase predictive biomarkers of motor recovery and functional prognosis at short and long term. To this end, we propose a single-center, prospective, randomised, controlled, and open label clinical trial with blinded end-point assessment. Adults diagnosed of acute ischaemic\u002Fhaemorrhagic stroke with mobility impaired in the upper-limb and included in a program of intensive CR (ICR) at hospital discharge will be included. Patients will be randomly assigned into two groups: ICR+IVR or only ICR and will be followed for one year to assess, at 3 and 12 months, motor strength in the upper-limb, functional dependence and quality of life. In blood samples obtained at admission (baseline) and at 12 months, proteins and microRNAs will be analysed to identify predictive biomarkers of recovery (motor and functional) and to determine the effect of IVR on neuroplasticity mechanisms. Genetic polymorphisms that may affect motor and functional recovery of patients treated with RC±RVI will also be analysed",[60],[164,165,166],"stroke","virtual reality","rehabilitation","2026-05-20",{"date":169,"type":38},"2026-05-27",{"date":171,"type":38},"2022-08-31",{"date":173,"type":22},"2026-06",{"name":175,"class":45},"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta",{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":187,"conditions":188,"keywords":191,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":204},"100523345","hospital-implementation-of-a-stroke-protocol-for-emergency-evaluation-and-disposition-100523345","NCT06094478","Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition","Implementation of a Stroke Protocol for Emergency Evaluation and Disposition","HI-SPEED","Inclusion Criteria:\n\n* Age \\>=18 years\n* Final diagnosis: AIS, ICH, or SAH\n\nExclusion Criteria:\n\n* Final diagnosis: TIA or stroke NOS\n* Age \\\u003C18 years\n* Comfort care measures on day 0 or 1\n* Left hospital against medical advice\n* Enrolled in clinical trial related to stroke that is competing with this study",{"count":185,"type":22},900,[25],"Most stroke patients are initially evaluated at the closest hospital but some need to be transferred to a hospital that can provide more advanced care. The \"Door-In-Door-Out\" (DIDO) process at the first hospital can take time making transferred patients no longer able to get the advanced treatments. This study will help hospitals across the US \"stand up\" new ways to evaluate stroke patients, decide who needs to be transferred, and transfer them quickly for advanced treatment.",[31,189,190],"Ischemic Stroke, Acute","Hemorrhagic Stroke",[192,193,194,195],"interhospital transfer","quality improvement","implementation science","stroke systems of care","2026-05-18",{"date":167,"type":38},{"date":199,"type":38},"2024-10-17",{"date":201,"type":22},"2028-07-31",{"name":203,"class":45},"University of Chicago",8,{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":216,"conditions":217,"keywords":222,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":235,"locationsCount":46},"100611983","evaluation-and-optimization-of-telephone-triage-using-artificial-intelligence-ai-models-for-the-detection-of-demands-for-time-dependent-pathology-at-the-emergency-and-urgent-care-coordination-center-ccue-100611983","NCT07247669","Evaluation and Optimization of Telephone Triage Using Artificial Intelligence (AI) Models for the Detection of Demands for Time-dependent Pathology at the Emergency and Urgent Care Coordination Center (CCUE).","Proyecto \"trIAje\": evaluación y optimización Del Triaje telefónico Mediante Modelos de Inteligencia Artificial (IA) Para la detección de Demandas Por patología Tiempo-dependiente en el Centro Coordinador de Urgencias y Emergencias (CCUE).","TrIAje Project","Inclusion Criteria:\n\nTelephone calls recorded with codes A36 + A58 (unconsciousness\u002Fcardiorespiratory arrest), A16 (respiratory distress), A23 (non-traumatic chest pain) and A54 (stroke).\n\nExclusion Criteria:\n\n* Demands with relevant information about the patient or the event incomplete or absent.",{"count":214,"type":22},5000000,"OBSERVATIONAL","Improving Telephone Triage in Emergency Calls with AI The Coordinating Centre for Urgencies and Emergencies in Andalusia (CCUE) handles thousands of calls every day. Each call needs to be assessed based on the information given over the phone to determine how serious the case is. The reasons for calling range from minor health issues to life-threatening emergencies like cardiac arrest (CPA).\n\nThis project focuses on improving telephone triage for four key emergency situations that often indicate severe or life-threatening conditions:\n\nUnconsciousness \u002F Cardiac arrest Difficulty breathing Chest pain (non-traumatic, possible heart-related issues) Stroke symptoms Our goal is to make telephone triage more accurate and efficient by using advanced Artificial Intelligence (AI) techniques, including Machine Learning (ML) and Natural Language Processing (NLP). These tools will help CCUE operators make better and faster decisions, ensuring that patients receive the right care as quickly as possible.\n\nHow it will be done:\n\nThe investigators will analyze anonymized historical call data from the emergency coordination system (CCR) and digital clinical records (HCDM). This includes:\n\nStructured data: Predefined fields, such as answers to standard triage questions.\n\nUnstructured data: Free-text notes and other information recorded during the call.\n\nA hybrid AI approach will be used, combining:\n\nTraditional AI methods (supervised learning and deep learning) to classify cases.\n\nGenerative AI techniques (advanced language models) to extract useful insights from free-text data.\n\nBuilding the Best Prediction Model\n\nTo find the most effective AI model, we will test different machine learning techniques, including:\n\nDecision Trees Random Forests Support Vector Machines (SVM) XGBoost Ensemble methods Neural Networks We will also analyze which questions and variables are the most important in predicting the severity of a case. Based on this, we will suggest improvements to the current triage questions to enhance accuracy.\n\nMeasuring Success\n\nWe will evaluate the AI model using key performance metrics, including:\n\nAccuracy (overall correctness) Sensitivity (ability to detect real emergencies) Specificity (ability to avoid false alarms) False Positive \\& False Negative Rates (how often the system makes mistakes) Likelihood Ratios (how well the system distinguishes between urgent and non-urgent cases) F1-Score \\& ROC Curve (overall performance indicators) Why This Matters This project will assess how effective the current telephone triage system is and develop a new AI-powered model to improve it. The goal is to help emergency operators quickly identify the most serious cases, reducing response times and improving patient outcomes. In the future, the investigators aim to integrate this improved AI model into the CCUE system to enhance emergency response across Andalusia.",[218,60,219,220,221],"Chest Pain","Respiratory Failure","Cardiac Arrest (CA)","Coma",[223,224,225,226,227,228],"Emergency Medical Communication Center","Triage Telephone","Emergency Medical Services","Priority","Machine Learning","Artificial Intelligence","2026-05-12",{"date":231,"type":38},"2026-05-13",{"date":233,"type":38},"2025-03-01",{"date":73,"type":22},{"name":236,"class":45},"Centro de Emergencias Sanitarias 061 Andalucía",{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":245,"targetDuration":247,"studyType":215,"phases":4,"briefSummary":248,"conditions":249,"keywords":253,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":273},"100635512","master-study-protocol-for-the-cohort-of-the-specialist-network-stroke-sn-strokestroke-core-100635512","NCT07553650","Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)","Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke) (Stroke-CORE)","Stroke-CORE","Inclusion Criteria:\n\n* Diagnosis of AIS or ICH; the AIS diagnosis may be diagnosed clinically or radiologically (i.e., focal neurological impairment of sudden onset, lasting more than 24 hours and of presumed vascular origin, or with proof of cerebral ischaemia corresponding to the clinical symptoms in neuroimaging); for ICH diagnosis requires clinical symptoms and radiological diagnosis of ICH\n* Hospital admission \\\u003C24h after symptom onset\n* Age 18+ years for the basic Modules AIS and ICH; age \\\u003C18 years for the basic Module paediatric stroke patients\n* Informed consent: Signed IC from patients capable of giving consent and understanding all content of the IC or IC of an appropriate patient representative or deferred consent, if patients are unable to consent themselves\n* Additional inclusion criteria are defined by the individual Modules\n\nExclusion Criteria:\n\n* In-hospital stroke\n* TIA\n* SAH\n* Stroke as a complication of a medical procedure\n* Enrolment in a randomised placebo-controlled interventional trial\n* Already enrolled in the SN STROKE base cohort",{"count":246,"type":22},12750,"90 Days","The Stroke-CORE cohort aims to provide a comprehensive and up-to-date understanding of stroke care in Germany. To achieve this, patients are followed along the entire continuum of care-from initial management before hospital admission, through acute treatment, rehabilitation, and follow-up care, to the prevention of recurrent strokes. Strokes occurring in childhood are also included in this cohort study.\n\nIn addition, the study seeks to establish effective structures for the early identification and inclusion of patients in clinical research (screening). In this context, structured screening processes are being implemented across all levels of care at participating sites within the Network University Medicine (NUM), a collaboration of German university hospitals. At the same time, the cohort serves as a platform within this network to systematically address open research questions in various areas of stroke care and to support the targeted planning and conduct of future clinical studies.\n\nThe study includes patients with ischemic stroke (caused by a blocked blood vessel) or intracerebral hemorrhage (bleeding within the brain). Participation takes place in different thematic modules, each focusing on specific aspects of the disease course and its management. These modules address, among other topics, acute hospital treatment, measures to prevent recurrent strokes (secondary prevention), possible complications, pre-hospital care, rehabilitation, follow-up care, and long-term outcomes such as physical recovery, independence in daily life, and cognitive functions including memory and concentration.\n\nAs part of the study, a range of data is collected. This includes sociodemographic information (such as age and living situation) as well as medical data, for example on prior conditions, diagnoses, treatments, and comorbidities. In addition, patients' health status is assessed at multiple time points in order to better understand the course of the disease. Depending on the level of participation, data collection may be complemented by the collection of biological samples, such as blood. These are obtained either during routine clinical procedures or through simple, minimally burdensome (non-invasive) methods.\n\nThe study is structured into several levels that differ in the scope and depth of data collection. The basic level includes essential information, while higher levels involve more detailed assessments. In addition, some levels include the collection of biological samples, and there are optional supplementary modules in which patients may participate voluntarily. This tiered approach allows participation to be flexibly adapted to the individual situation while contributing to a nuanced and comprehensive understanding of stroke care.",[250,251,60,64,252],"Intracerebral Haemorrhage","Paediatric Stroke","Ischemic Stroke",[64,254,255,251,256,257,258,259,260,261,262,263],"ischemic stroke","Intracerebral Hemorrhage","Cerebrovascular Disorders","Brain Diseases","Vascular Diseases","Cardiovascular Diseases","Brain Infarction","Embolic Stroke","Thrombotic Stroke","Acute","2026-04-23",{"date":266,"type":38},"2026-04-28",{"date":268,"type":22},"2026-05-01",{"date":270,"type":22},"2030-06-30",{"name":272,"class":45},"Charite University, Berlin, Germany",12,{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":7},"100509295","treatment-with-endovascular-intervention-for-stroke-patients-with-existing-disability-100509295","NCT05911568","Treatment With Endovascular Intervention for STroke Patients With Existing Disability","TESTED","Inclusion Criteria:\n\n1. Adult patients (≥18 years)\n2. Moderate-to-severe pre-stroke functional disability, defined as mRS 3-4, for at least 3 months prior to stroke onset\n3. Presenting to study hospital within 24 hours of last known well time\n4. Diagnosis of acute ischemic stroke\n5. Intracranial causative occlusion of the internal carotid artery or the M1 or dominant M2 segments of the middle cerebral artery visualized on the baseline CT(or MR) angiogram\n6. Presenting CT Alberta Stroke Program Early CT (ASPECT) score ≥3 or MRI ASPECT score ≥4\n7. Presenting NIH Stroke Scale score ≥6\n8. Informed consent from patient if competent or from legally authorized representative\n\nExclusion Criteria:\n\n1. Known diagnosis of a terminal cancer or terminal illness at the time of stroke\n2. Assessment of pre-stroke functional status cannot be performed during the hospital stay\n3. Pre-stroke disability deemed temporary in the investigator's opinion (for example, recovering from a general medical illness or traumatic bodily injury)",{"count":282,"type":22},1060,"TESTED will compare the risks and benefits of endovascular thrombectomy (EVT) to medical management (no EVT) in ischemic stroke patients who have a blockage in one of the large blood vessels in the brain and have a moderate-to-severe disability prior to their stroke.",[64,31,90],"2026-04-14",{"date":287,"type":38},"2026-04-15",{"date":289,"type":38},"2023-11-16",{"date":291,"type":22},"2028-04-15",{"name":293,"class":45},"University of Cincinnati",{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":304,"briefSummary":305,"conditions":306,"keywords":309,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":46},"100566670","phase-3-efficacy-and-safety-of-tenecteplase-bridging-mechanical-thrombectomy-for-acute-large-vessel-occlusion-stroke-100566670","NCT06658197","Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke","Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusive Stroke(TNK-LVO) :a Phase 3, Multicentre, Open-label, Randomised Controlled Trial","TNK-LVO","Inclusion Criteria:\n\n1. Age is ≥18 years.\n2. AIS symptom onset ≤4.5 hours, onset time refers to the time the patient was last known to be well. (Recommendation time from thrombolysis to puncture within 60 minutes).\n3. Arterial occlusion of the internal carotid artery (ICA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery on computed tomography angiography (CTA) or magnetic resonance angiography (MRA).\n4. Prestroke mRS score ≤2.\n5. Informed consent from the patient or legally authorised representative.\n\nExclusion Criteria:\n\n1. Patients diagnosed with hemorrhagic stroke (including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural\u002Fextradural hematoma, etc.) or other related conditions identified by CT.\n2. Contraindication to imaging examinations involving contrast agent injection.\n3. Patients presenting with clinical symptoms of coma (NIHSS Score Item 1a = 3).\n4. History of intracranial hemorrhage.\n5. History of severe head trauma or stroke within the past 3 months.\n6. Intracranial or intraspinal surgery within the past 3 months.\n7. Major surgery within the past 2 weeks.\n8. Gastrointestinal or urinary tract bleeding within the past 3 weeks.\n9. Intracranial tumor, arteriovenous malformation, or giant intracranial aneurysm.\n10. Active visceral bleeding.\n11. Aortic arch dissection.\n12. Arterial puncture at a non-compressible site within the past week.\n13. Uncontrolled hypertension despite active antihypertensive treatment: Systolic Blood Pressure \\> 180 mmHg or Diastolic Blood Pressure \\> 100 mmHg.\n14. Acute hemorrhagic tendency, including platelet count \\\u003C 100 × 10⁹\u002FL or other conditions.\n15. Heparin treatment received within the past 24 hours.\n16. For patients on oral anticoagulants: INR \\> 1.7 or PT \\> 15 seconds.\n17. Use of direct thrombin inhibitors or direct Factor Xa inhibitors within the past 48 hours.\n18. Blood glucose \\\u003C 2.8 mmol\u002FL or \\> 22.2 mmol\u002FL.\n19. Hypodensity affecting \\> 1\u002F3 of the middle cerebral artery territory or an equivalent proportion of the basilar artery territory on non-contrast CT.\n20. Rapidly improving symptoms as determined by the investigator.\n21. Participation as a subject in another research study within the past 30 days.\n22. Any terminal illness where life expectancy is considered not to exceed 1 year.\n23. Any condition where, in the judgment of the investigator, the study treatment might pose a risk to the patient or affect the patient's participation in the study.\n24. Pregnant women.\n25. Known allergy to the active ingredients (Alteplase, Tenecteplase) or any excipients.",{"count":303,"type":22},850,[87],"A phase III, multicentre, prospective, randomised, open-label, blinded-endpoint clinical trial will evaluate two thrombolytic agents for the treatment of acute large vessel occlusion stroke within 4.5 hours from symptoms onset: intravenous tenecteplase bridging mechanical thrombectomy vs. intravenous alteplase bridging mechanical thrombectomy.",[90,31,307,308],"Thrombosis, Brain","Drug Effect",[310,311],"Ischemic stroke","Tenecteplase","2026-04-08",{"date":314,"type":38},"2026-04-09",{"date":316,"type":38},"2025-12-25",{"date":318,"type":22},"2027-06-01",{"name":320,"class":45},"Xuanwu Hospital, Beijing",{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":17,"minAge":327,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":23,"phases":330,"briefSummary":331,"conditions":332,"keywords":333,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":46},"100316605","wearable-mci-to-reduce-muscle-co-activation-in-acute-and-chronic-stroke-100316605","NCT03401762","Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke","Inclusion Criteria:\n\nChronic stroke participants\n\n* Hemiparesis from first ever stroke at least 6 months prior to screening\n* Severe motor impairment (FMA of 7-30)\n* At least some voluntary shoulder and elbow muscle activation.\n\nAcute stroke participants\n\n* Hemiparesis from first ever stroke within the past 21 days\n* Severe motor impairment (FMA of 3-20), or total Manual Motor Score of 1-8 combined in Shoulder Abduction and Finger Extensors\n\nExclusion Criteria:\n\n* Cognitive impairment with at least moderately impaired attention, or unable to follow instructions of the MCI task\n* Visual impairment (such as hemianopia) preventing full view of the screen\n* Anesthesia or neglect in the affected arm, or visual hemineglect (score of 2 on the NIH Stroke Scale Extinction and Inattention subtest).\n* Participation in another study on the affected arm within 6 weeks of enrollment or any pharmacological study\n* Inability to understand or follow commands in English due to aphasia or other reason\n* Diffuse or multifocal infarcts\n* Substantial arm pain preventing participation for 90 minutes a day\n* New spasticity treatment (pharmacological or Botox)","21 Years",{"count":329,"type":22},96,[25],"The purpose of the study is to explore the feasibility of using a wearable device, called a myoelectric-computer interface (MCI), to improve arm movement in people who have had a stroke.\n\nImpaired arm movement after stroke is caused not just by weakness, but also by impaired coordination between joints due to abnormal co-activation of muscles. These abnormal co-activation patterns are thought to be due to abnormal movement planning.The MCI aims to reduce abnormal co-activation by providing feedback about individual muscle activations.\n\nThis randomized, controlled, blinded study will test the home use of an MCI in chronic and acute stroke survivors.",[64,31],[166],"2026-04-07",{"date":312,"type":38},{"date":337,"type":38},"2018-01-15",{"date":339,"type":22},"2027-04",{"name":341,"class":45},"Northwestern University",{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":350,"enrollmentInfo":351,"targetDuration":247,"studyType":215,"phases":4,"briefSummary":353,"conditions":354,"keywords":356,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":46},"100380222","circulating-non-coding-rna-in-acute-ischemic-stroke-with-endovascular-treatment-evtrna-100380222","NCT04230785","Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)","Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)","EVTRNA","Inclusion Criteria:\n\n* Aged 18 years or older\n* Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan\n* Within 24 hours of symptom onset and treat with endovascular therapy\n* Good performance status\n* Signed an approved informed consents\n\nExclusion Criteria:\n\n* a history of hemorrhagic infarction, chronic kidney\u002Fliver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases","90 Years",{"count":352,"type":22},300,"EVTRNA is to analyze the differentiated expression pattern of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA) by next-generation sequencing in acute ischemic stroke patients before and\u002For after endovascular treatment. The candidate circRNA\u002FlncRNA\u002FmiRNA will be verified as the biomarker and regulator for progression and prognosis of acute ischemic stroke with endovascular treatment. Further, the candidate non-coding RNA will be used to evaluate the effect of endovascular treatment on both peripheral and central immune after stroke.",[31,90,355],"Endovascular Treatment",[357,358,359,360,361],"acute ischemic stroke","noncoding RNA","endovascular treatment","clinical significance","outcome","2026-04-06",{"date":314,"type":38},{"date":365,"type":38},"2020-03-15",{"date":367,"type":22},"2026-12-01",{"name":369,"class":45},"Nanjing First Hospital, Nanjing Medical University",{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":23,"phases":378,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":385,"leadSponsor":387,"locationsCount":46},"100631931","study-on-the-optimal-head-position-for-patients-with-severe-acute-ischemic-stroke-100631931","NCT07507097","Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke","Inclusion Criteria\n\n1. Age ≥ 18 years\n2. Meeting the diagnostic criteria for acute ischemic stroke according to the \"Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023\": ①Acute onset, ②Focal neurological deficits, with a few having global neurological deficits, ③Imaging shows a corresponding lesion or symptoms\u002Fsigns persist for more than 24 hours, ④Exclusion of non-vascular causes, ⑤Brain CT\u002FMRI excludes cerebral hemorrhage\n3. Meeting the criteria for severe ischemic stroke patients: severe neurological deficits at admission \\[for example, National Institutes of Health Stroke Scale (NIHSS) score≥15\\]\n4. First-time diagnosed ischemic stroke patients who undergo thrombolysis and\u002For thrombectomy reperfusion treatment\n5. Time from onset to randomization within 24 hours\n6. Informed consent obtained and signed by the patient or their family\n\nExclusion Criteria\n\n1. Known pregnancy or breastfeeding, or positive pregnancy test before randomization\n2. Expected survival time less than 3 months (such as with malignant tumors, severe cardiopulmonary diseases, etc)\n3. Already participating in other interventional clinical studies that may affect outcome assessment\n4. Other situations deemed by the investigator as unsuitable for participation in this study or that may pose significant risks to the patient (such as inability to understand and\u002For comply with study procedures and\u002For follow-up due to mental illness, cognitive or emotional disorders)\n5. Presence of brain midline shift or herniation, ventricular mass effect\n6. Patients with limited head elevation (or patients unable to cooperate with postural intervention due to their condition\u002Frecovery needs, etc.)\n7. Presence of respiratory infection symptoms such as fever, cough, or sputum production at the time of admission",{"count":377,"type":22},1508,[25],"Stroke is the second leading cause of death and the third leading cause of disability worldwide, with an increasing incidence. Reperfusion therapy after cerebral ischemia is one of the most practical and effective treatments for ischemic stroke globally. However, the nursing care and management of hemodynamics during the acute phase after reperfusion therapy for ischemic stroke have always been key and challenging aspects of clinical work. Stable hemodynamic status can prevent hypoperfusion or hyperperfusion of brain tissue, reduce damage to the ischemic core and penumbra areas, and consequently decrease cerebral edema, elevated intracranial pressure, and the associated neurological damage and worsening clinical outcomes.\n\nHead positioning, as a simple, economical, and effective adjunctive treatment for managing patients undergoing reperfusion therapy, has gradually received attention. During the acute phase of stroke, brain tissue is in a state of ischemia and hypoxia. Lying flat may increase blood and oxygen supply to the brain tissue, providing a certain degree of protection, but it may also have some impact on swallowing and lung function. Raising the head of the bed can help venous blood return from the head and may reduce cerebral edema to some extent, but it can also affect perfusion of ischemic brain tissue to a certain degree. In the acute phase after successful reperfusion, it remains a clinical challenge to maintain stable cerebral blood supply (hemodynamic stability) through nursing care. Head positioning (lying flat or elevating the head of the bed) is a simple, economical nursing measure that may affect cerebral blood flow. However, for severely affected stroke patients like you, there is no clear international consensus on whether maintaining a flat position (0°) or elevating the head of the bed 30° within the first 24 hours after treatment is more beneficial for long-term recovery. Previous studies have shown inconsistent results, so more rigorous research is needed to answer this question.\n\nThe primary purpose of this study is to determine that a 30° position during the acute phase of severe ischemic stroke is safe. The secondary purpose is to evaluate whether a 30° position in the acute phase improves 90-day outcomes compared to a 0° position (assessed using the modified Rankin Scale).\n\nThis study is a randomized controlled trial. This means you will be randomly assigned (like a coin toss) to one of the following two groups: Experimental group: within 24 hours of admission, maintain the head and bed elevated at 30°. Control group: within 24 hours of admission, remain completely flat (0°). Interventions and methods: Both head positions are commonly used basic nursing measures in neurological intensive care. Lying flat may help increase blood supply to the brain, while elevating the head of the bed may help reduce cerebral edema and the risk of aspiration. This study aims to scientifically compare which angle is better for your long-term recovery. Procedures: Research nurses will use a special angle ruler to ensure your head position is accurate. During the 24-hour intervention, we need you to maintain the assigned position as much as possible. Considering your comfort and necessary medical care (such as back patting and skin inspection), brief interruptions are allowed (no more than three times for the flat position group, with each interruption less than 30 minutes). Legal Compliance: Head positioning management is a routine nursing procedure. This study only conducted standardization and comparative research on it, and did not involve the use of any experimental drugs or high-risk devices. It has passed ethical review.",[60],"2026-03-29",{"date":383,"type":38},"2026-04-02",{"date":268,"type":22},{"date":386,"type":22},"2029-04-30",{"name":388,"class":45},"West China Hospital",{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":401,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":46},"100582548","virtual-reality-rehabilitation-for-stroke-patients-in-the-hospital-and-at-home-100582548","NCT06864741","Virtual Reality Rehabilitation for Stroke Patients in the Hospital and at Home.","Acute Stroke Rehabilitation Using a Low-cost Virtual Reality Platform: a Pilot Study.","Inclusion Criteria:\n\n* clinical diagnosis of first-time ischemic stroke involving the middle cerebral artery, confirmed by CT or MRI;\n* score between 6 and 40 on Fugl-Meyer Assessment's Upper Limb Extremity Subscore (FM - UE), indicating moderate to severe motor deficit;\n* ability and willingness to provide consent (score of 18 or more on the Montreal Cognitive Assessment) or assent (for scores lower than 18 on MoCA with consent provided by an authorized third party with the necessary legal authority to consent on behalf of patient)\n* INPATIENT ARM: less than 5 weeks since stroke onset with admission to Valley Regional Hospital in Kentville, NS, Canada\n* OUTPATIENT ARM: less than 3 months since stroke onset with discharge to home setting located within 1 hour drive of Valley Regional Hospital in Kentville, NS, Canada\n\nExclusion Criteria:\n\n* brainstem, cerebellar or bilateral stroke lesion\n* a secondary neurological condition (e.g., Parkinson's disease)\n* musculoskeletal injuries interfering with task performance\n* an uncorrected visual deficit due to stroke or other etiologies\n* apraxia as identified by clinical assessment",{"count":397,"type":22},40,[25],"The goal of this clinical trial is to test whether a low-cost virtual reality (VR) motor rehabilitation platform can improve motor recovery in people recovering from a first-time ischemic stroke both in the hospital and at home. The study focuses on adults aged 18 and older who have experienced moderate to severe upper limb motor deficits.\n\nThe main questions it aims to answer are:\n\n* Can VR-based motor therapy improve upper limb motor function compared to standard care?\n* Is VR-based motor therapy a feasible and acceptable treatment option for stroke patients?\n\nResearchers will compare patients receiving VR therapy to those receiving standard care to see if the VR therapy leads to greater improvements in motor recovery and more positive patient experiences.\n\nParticipants will:\n\n* Complete standardized assessments of motor function and quality of life at multiple time points.\n* Participate in VR therapy sessions (if in the treatment group), using gamified activities designed to improve upper limb movement.\n* Provide feedback on their experience with the VR system, including ease of use, motion sickness, and engagement.\n\nThis study will help determine whether VR-based rehabilitation can be a practical, effective way to improve access to therapy and recovery outcomes for stroke patients, especially in rural settings with limited rehabilitation resources.",[60],[164,166,402,165],"motor disorder","2026-03-16",{"date":405,"type":38},"2026-03-18",{"date":407,"type":38},"2025-10-15",{"date":409,"type":22},"2027-06",{"name":411,"class":45},"Nova Scotia Health Authority",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":431},"100483689","effective-translation-of-endovascular-thrombectomy-trials-into-real-world-practice-in-the-asia-pacific-100483689","NCT05578300","Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific","Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific: a Multicenter, Prospective Registry (ENDURE-APAC)","Inclusion Criteria:\n\n* Patient who are over 18 years of age.\n* Patient with ischemic stroke with suspected large vessel occlusion (LVO), defined as occlusion of the internal carotid artery (ICA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery (BA).\n\nExclusion Criteria:\n\n* Patient with isolated vertebral artery occlusion not involving the BA.",{"count":420,"type":22},350,"As a major breakthrough of acute stroke treatment over the past decade, endovascular thrombectomy (EVT) drastically improved neurological recovery and survival in patients with large vessel occlusion (LVO) ischemic strokes in major clinical trials. Nevertheless, much remained uncertain about the implementation of scientific evidence of EVT into real-world benefits. For instance, healthcare policies that influence critical time-matrices, endovascular thrombectomy techniques that may enhance success rate or prevent complications, or advanced imaging techniques that allow precise prognosis or expansion of treatment populations, should be evaluated. On the other hand, capturing LVO patients who were not able to undergo EVT may reveal the gap between clinical trials and real-world practice in the Asia-Pacific.\n\nIn this multicenter prospective collaboration across the Asian-Pacific, the investigators aim to evaluate the determinants of effective EVT in the real-world setting.",[252,64,31,90,257,423],"Major Adverse Cardiovascular Event",{"date":405,"type":38},{"date":426,"type":38},"2022-10-21",{"date":428,"type":22},"2032-12-31",{"name":430,"class":45},"Chinese University of Hong Kong",3,{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":23,"phases":442,"briefSummary":443,"conditions":444,"keywords":445,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":458},"100579561","delay-avoiding-primary-evaluation-for-thrombectomy-of-acute-stroke-patients-with-large-vessel-occlusion-in-the-angiography-suite-100579561","NCT06825897","Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe","Delay Avoiding Primary Evaluation for Thrombectomy for Acute Stroke Patients With Large Vessel Occlusion in the Angiography Suite (DIRECT) Trial","DIRECT","Inclusion Criteria:\n\nTo be eligible for participation in the DIRECT trial, an individual must meet all of the following criteria:\n\n1. Age: ≥ 18 years of age.\n2. Clinical Presentation: Present to a participating TSC with signs or symptoms suggestive of acute LVO stroke.\n3. Stroke Severity: Baseline NIHSS of 10 or higher.\n4. Time since LKW: Time from LKW to arrival at the TSC must be within 7 hours.\n\nAdditional criteria\n\nFor all Interfacility Transfers:\n\n1\\. If imaging was performed at the outside facility, the time from the first imaging to arrival at the thrombectomy center must exceed 90 minutes.\n\nFor all the Conventional Triage Arm, participants must also meet the following criteria:\n\n1. Presence of a qualifying LVO by CTA or MRA imaging; or\n2. For Large Core Patients: Patients with large core infarcts (CT-ASPECT score ≤ 5, DWI-ASPECT score ≤ 5, or infarct volume ≥ 70 cc) will be enrolled, irrespective of treatment decisions regarding embolectomy.\n\nFor all DTAS Arm:\n\n1\\. Patients who do not have LVO occlusions in the angiography suite assessment (ICH, distal occlusions or mimics) will be enrolled, irrespective of treatment decisions regarding embolectomy.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in the trial:\n\n1. Time Restrictions: Presentation to a thrombectomy-capable center more than 7 hours from LSW.\n2. Imaging Criteria for Interfacility Transfer Patients: At sites enrolling transfer patients, any patient arriving from an outside hospital with time from imaging study at the presenting hospital to arrival at the TSC not exceeding 90 minutes.\n3. Hemorrhagic Stroke: Presence of intracranial hemorrhage on brain imaging in the conventional strategy as Heidelberg that renders thrombectomy contraindicated.",{"count":441,"type":22},2039,[25],"The purpose of this study is to compare two strategies for treating adults with suspected large vessel occlusion stroke within 7 hours of symptom onset. Researchers will evaluate whether direct transfer to the neurointerventional angiography suite improves recovery and reduces disability compared to the conventional approach of first being evaluated in the emergency department. The study will also assess safety and other health outcomes to guide care for stroke patients.",[31],[446,447,448],"Large Vessel Occlusion","Acute Ischemic Stroke","Pragmatic Clinical Trial","2026-03-11",{"date":451,"type":38},"2026-03-13",{"date":453,"type":38},"2026-01-27",{"date":455,"type":22},"2028-04-30",{"name":457,"class":45},"Santiago Ortega Gutierrez",6,{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":23,"phases":467,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":480},"100416363","we-trust-workflow-optimization-to-reduce-time-to-endovascular-reperfusion-for-ultra-fast-stroke-treatment-100416363","NCT04701684","WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)","Inclusion Criteria:\n\n* Subject is 18 years of age or older, or of legal age to give informed consent per state or national law.\n* Baseline NIHSS score obtained prior to randomization must be equal or higher than 10 points.\n* Subjects with no significant pre-stroke functional disability (modified Rankin scale 0 - 2).\n* Subjects suspected of acute ischemic stroke with an estimated arrival time at a stroke center (clinical investigational site participating in this study) \\\u003C 6 hours from symptom onset OR wake-up stroke with time last known well of \\\u003C 12 hours and symptoms discovered within 6 hours from arrival time at a stroke center. Symptom onset is defined as point in time the patient was last known well (at baseline).\n* Informed consent obtained from patient or his or her legally designated representative (if locally required).\n* Angiography suite immediately available.\n* Endovascular treatment team immediately available (Neurologist, Neurointerventionalist, Anesthesiologist, Nursing, Technicians as per local standard practice)\n\nExclusion Criteria:\n\nClinical exclusion criteria:\n\n* Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR \\> 3.0\n* Known baseline platelet count \\\u003C 30.000\u002FμL\n* Baseline blood glucose of \\\u003C 50mg\u002FdL (\\\u003C 2.78mmol\u002Fl)\n* For patients receiving thrombolysis: severe, sustained hypertension (SBP \\> 185 mm Hg or DBP \\> 110 mm Hg). Note: If the blood pressure can be successfully reduced and maintained at the acceptable level using AHA\u002FASA guidelines recommended medication (including IV antihypertensive drips), the patient can be enrolled.\n* Patients from a transfer center (Primary Stroke Center) with a CT\u002FMR that is not required to be redone in the Comprehensive Stroke Center as per discretion of the physician or per local standards (e.g. CT\u002FMR less than 90 minutes old).\n* Patients in coma (NIHSS item of consciousness \\>1) defined as totally unresponsive; responding only with reflexes or being areflexic (Intubated patients for transfer could be randomized only in case an NIHSS is obtained by a neurologist prior transportation).\n* Patients with extreme vomiting\n* Patients that are extremely agitated\n* Seizures at stroke onset which would preclude obtaining a baseline NIHSS\n* Serious, advanced, or terminal illness with anticipated life expectancy of less than one year.\n* Patients acquired stroke while in-hospital\n* History of life-threatening allergy (more than rash) to contrast medium\n* Cerebral vasculitis\n* Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations, mRS score at baseline must be ≤2. This excludes patients who are severely demented, require constant assistance in a nursing home type setting or who live at home but are not fully independent in activities of daily living (toileting, dressing, eating, cooking and preparing meals, etc.)\n* Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas).\n* Patients with unstable clinical status who require emergent life support care\n* Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.\n* Subject participates in a potentially confounding drug or device trial during the course of the study.\n* Woman of childbearing potential who is known to be pregnant on admission.\n* Subject meets an exclusion criteria according to national law (e.g. age, pregnant woman, breast feeding woman)\n* Subject is Philips employee or their family members residing with this Philips employee.",{"count":466,"type":22},594,[25],"The WE-TRUST study is a multi-center randomized clinical trial to assess the impact of a Direct to Angio Suite (DTAS) workflow on stroke patient outcomes.",[31],"2026-03-03",{"date":472,"type":38},"2026-03-05",{"date":474,"type":38},"2021-06-23",{"date":476,"type":22},"2027-04-01",{"name":478,"class":479},"Philips Clinical & Medical Affairs Global","INDUSTRY",23,{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":489,"briefSummary":490,"conditions":491,"keywords":492,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":502,"leadSponsor":504,"locationsCount":505},"100591074","fusion-imaging-in-endovascular-thrombectomy-for-acute-ischemic-stroke-100591074","NCT06975696","Fusion Imaging in Endovascular Thrombectomy for Acute Ischemic Stroke","FUSE-IT","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Eligible for an EVT procedure\n\nExclusion Criteria:\n\n1. Previous inclusion in this study\n2. No access to a preoperative CTA",{"count":352,"type":22},[25],"Endovascular thrombectomy (EVT) is the standard of care for acute ischemic stroke (AIS) caused by a large vessel occlusion.\n\nSuccessful recanalization is one of the most important factors for a good patient outcome, especially when obtained within 30 minutes from groin puncture, and the procedural success-rate reaches above 90% at treating centers of excellence. There are however a portion of cases where recanalization is not achieved, which in some cases are attributed to difficult arterial anatomy affecting the ability to catheterize the precerebral target vessel.\n\nIn the latest angiography platforms, 3D reconstructions of the aortic, cervical and intracranial arteries from the preprocedural CT angiography can be fused with periprocedural 2D digital subtraction angiography and\u002For fluoroscopy images, so called 2D\u002F3D Fusion imaging. The preparation steps can be done before patient arrival to the angiography suite and the image fusion can be done in less than a minute during patient preparation. Previous observational studies have shown that the use of fusion imaging during EVT procedures may decrease failed target vessel access and increase procedural success rate and first-pass recanalization rate, without prolonging the procedure.\n\nThe purpose of this study is to assess the use of fusion imaging in EVT procedures and its effect on target vessel access, recanalization success-rate and procedure times.",[60],[64,493,494,495,496,497],"endovascular thrombectomy","fusion","interventional neuroradiology","procedure","mTICI","2026-03-02",{"date":500,"type":38},"2026-03-04",{"date":498,"type":38},{"date":503,"type":22},"2027-05-31",{"name":75,"class":45},4,{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":513,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":46},"100438662","impact-of-covid-19-vaccines-on-cerebrovascular-health-100438662","NCT04992195","Impact of COVID-19 Vaccines on Cerebrovascular Health","Impact of COVID-19 Vaccines on Cerebrovascular Health - a Population-based Study","Inclusion Criteria:\n\nAll consecutive citizens in the CUHK Brain Health Longitudinal Study cohort who received baseline MRI brain.\n\nExclusion Criteria:\n\n1. Citizens with clinically evident stroke or dementia prior to recruitment; or\n2. Citizens who are unable to provide an informed consent; or\n3. Citizen with contraindications to MRI brain, e.g., non-MRI compatible implants, claustrophobia, etc; or\n4. Citizens who had no baseline MRI brain assessment.",true,{"count":56,"type":22},"Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may reduce the transmission of and achieve population immunity against the COVID-19 pandemic, which accounted for more than 3.75million deaths worldwide. With World Health Organization's (WHO) effort on ensuring equitable access to COVID-19 vaccines, vaccination rate may increase in the near future.\n\nOn the other hand, vaccination hesitancy has emerged as a major hindrance on the global vaccination campaigns in certain areas due to safety concerns, social factors, and public health policies. For instance, a recent survey conducted in Hong Kong showed a low vaccine acceptance rate of 37%. Long-term safety concerns and post-vaccination events relayed by the social media maybe reasons for vaccination hesitancy. Among which, cerebrovascular accidents (CVA) after vaccination were one of the most frequently reported post-vaccination events. These reports ranged from ischemic strokes in elderly patients with multiple cardiovascular co-morbidities, to hemorrhage strokes in otherwise \"young-and-fit\" adults. While many of these events were investigated by the COVID-19 immunization expert committee, an important premise to address the apprehension of CVA after vaccination is the provision of evidence-based information of the impact of COVID-19 vaccines on brain health.\n\nIn this prospective, longitudinal, observational study, we aim to elucidate the relationship between COVID-19 vaccines and cerebrovascular health in healthy citizens in a population-based cohort.",[64,31,90,517,518,519,257,423,520,521],"Dementia","Brain Ischemia","Alzheimer Disease","Arterial Thromboembolism","Venous Thromboembolism","2026-02-21",{"date":524,"type":38},"2026-02-24",{"date":526,"type":38},"2021-07-05",{"date":528,"type":22},"2026-12-31",{"name":430,"class":45},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":513,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":539,"conditions":540,"keywords":546,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":557},"100331231","cuhk-brain-health-longitudinal-study-100331231","NCT03592563","CUHK Brain Health Longitudinal Study","BHS","Inclusion Criteria:\n\n1. Adult ≥ 18 years of age\n2. Fulfilling criteria for membership in one of these three groups:\n\n   * Red group: established diagnosis of one or more neurological and\u002For psychiatric conditions\n   * Yellow group: high-risk to develop one or more neurological and\u002For psychiatric conditions\n\n     1. family history (first degree relative) one or more neurological and\u002For psychiatric conditions\n     2. examination, imaging or laboratory findings consistent with pre-symptomatic stages of one or more neurological and\u002For psychiatric disorders\n   * Green group: not meeting criteria for Red or Yellow groups, but interested in longitudinal research on maintenance and\u002For improvement of brain health\n3. Subject provides informed consent by signing and dating the written informed consent form\n4. Subject is willing to answer health questionnaires and be followed longitudinally\n\nExclusion Criteria:\n\n* None",{"count":538,"type":22},5000,"The goal of this study is to develop a large longitudinal cohort of individuals diagnosed with or at high risk for brain diseases (both neurological and psychiatric in nature), in order to identify risk factors that contribute to neurological and psychiatric diseases over time. The investigators seek to capture relevant information from medical records, electronically administered questionnaires and follow up phone-based interviews. The investigators expect to eventually have sufficient power from our dataset to examine risk factors for a variety of brain disorders, both individually and in aggregate. Our ultimate goal is to offer scientifically validated ways to preserve and promote brain health by working with our patients' needs and tracking their progress over time.",[90,541,64,31,517,518,257,519,542,543,544,545],"Stroke Syndrome","Health Attitude","Health Knowledge, Attitudes, Practice","Health Personnel Attitude","Healthy Aging",[164,547,548,549,550],"dementia","Alzheimer disease","Health Brain","Health knowledge",{"date":524,"type":38},{"date":553,"type":38},"2019-07-01",{"date":555,"type":22},"2048-12-31",{"name":430,"class":45},2,{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":566,"enrollmentInfo":567,"targetDuration":4,"studyType":23,"phases":569,"briefSummary":571,"conditions":572,"keywords":573,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":582,"locationsCount":46},"100625541","phase-2-advancing-reperfusion-therapy-for-ischemic-stroke-safety-and-efficacy-of-anakinra-for-futile-reperfusion-following-endovascular-treatment-in-patients-with-acute-ischemic-stroke-100625541","NCT07423975","Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke","Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke (SAFE)","ARTS-SAFE","Inclusion Criteria:\n\n* Age between 18-80 years old (both inclusive);\n* Acute ischemic stroke symptom onset within 24 hours; including wake-up stroke and unwitnessed stroke, onset time refers to \"last-seen normal time\";\n* Pre-stroke modified Rankin scale (mRS) score ≤1;\n* Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (both inclusive);\n* Internal carotid artery (ICA) or middle cerebral artery (MCA) M1\u002FM2 occlusions confirmed by CTA\u002FMRA and responsible for the signs and symptoms of acute ischemic stroke;\n* Successful recanalization (eTICI 2b50-3) after endovascular treatment;\n* Written informed consent from patients or their legally authorized representatives.\n\nExclusion Criteria:\n\n* Allergy to Anakinra;\n* NIHSS consciousness score 1a \\>2, or epileptic seizure, hemiplegia after seizures (Todd's palsy) or other neurological\u002Fmental illness such that the patient is not able to cooperate or unwilling to cooperate;\n* Unable to perform CTP or PWI;\n* Acute or past intracerebral hemorrhage (ICH) (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural\u002Fepidural hematoma) confirmed by CT or MRI;\n* Multiple arterial occlusion (e.g., bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion);\n* Glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin or serum creatinine level \\>2.5 mg\u002FdL;\n* Suspected septic embolism or infective endocarditis;\n* Neutropenia (ANC \\\u003C1.5 × 109\u002FL);\n* Known active or recurrent liver disease (including cirrhosis, hepatitis B and C; positive or indeterminate laboratory results), or alanine aminotransferase (ALT)\u002Faspartate aminotransferase (AST) levels \\>3 times the upper limit of normal (ULN) or total bilirubin \\>2 times ULN;\n* History of malignancy other than basal cell carcinoma of the skin;\n* History or evidence of active or latent tuberculosis infection, or presence of tuberculosis risk factors including but not limited to: close contact with active tuberculosis patients within the past 12 months;\n* Any terminal illness such that the patient would not be expected to survive more than 1 year;\n* Pregnant women, nursing mothers, or reluctance to use effective contraceptive measures during the period of trial;\n* Unlikely to adhere to the trial protocol or follow-up;\n* Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;\n* Participation in other interventional clinical trials within the previous 3 months.","80 Years",{"count":568,"type":22},159,[570],"PHASE2","The investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to explore the safety and efficacy of different dose of Anakinra compared to standard medical care for patients with acute ischemic stroke who have achieved successful recanalization after endovascular thrombectomy.",[60,355],[357,359,574,575],"successful recanalization","Anakinra","2026-02-14",{"date":578,"type":38},"2026-02-20",{"date":580,"type":22},"2026-03-01",{"date":528,"type":22},{"name":583,"class":45},"Beijing Tiantan Hospital",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":592,"conditions":593,"keywords":594,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":46},"100593261","proving-utility-of-a-new-field-cycling-mri-prototype-in-acute-stroke-patients-100593261","NCT07004140","Proving Utility of a New Field-cycling MRI Prototype in Acute Stroke Patients","PUFFINS 3","Inclusion Criteria:\n\n* Acute stroke (\\\u003C24 hours from symptom onset).\n* NIHSS ≥4 and \\\u003C25 with cortical involvement and\u002For large vessel occlusion on baseline imaging.\n* Able to undergo 3T and FCI MRI \\\u003C24h of onset.\n* With or without thrombolysis.\n\nExclusion Criteria:\n\n* Contraindications to MRI.\n* Medically unstable.\n* Unable to comprehend or comply with instructions regarding scanning\n* Prior mRS of \\>3.\n* Identified for thrombectomy.\n* Non-stroke pathology or previous cortical infarct on CT scan \\> 1\u002F3 of middle cerebral artery territory.",{"count":397,"type":22},"The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can show changes in the brain within the first day of a stroke due to a blocked blood vessel or bleeding in the brain. The main question it aims to answer is:\n\n• Can FCI identify brain tissue that might recover within the first few hours after a stroke begins?\n\nParticipants will undergo a standard MRI scan and an FCI scan, as soon as possible after hospital admission.\n\nParticipants who have had a blocked blood vessel will also provide a blood sample and will have a follow up visit at 30 days for repeat of both scans and providing another blood sample.",[60],[64,595,596],"Field-Cycling Imaging","FCI","2026-01-26",{"date":453,"type":38},{"date":600,"type":38},"2025-09-16",{"date":602,"type":22},"2026-05",{"name":604,"class":45},"University of Aberdeen",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":611,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":613,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":614,"conditions":615,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":46},"100276501","early-neurological-clinical-recovery-3-months-after-endovascular-treatment-of-an-acute-ischemic-stroke-100276501","NCT02879123","Early Neurological Clinical Recovery, 3 Months After Endovascular Treatment of an Acute Ischemic Stroke","Assessment of Patients' Early Neurological Clinical Recovery, 3 Months After Endovascular Treatment of an Acute Ischemic Stroke","AVC-endovasc","Inclusion Criteria:\n\n* acute ischemic stroke\n* endovascular treatment\n\nExclusion Criteria:\n\n* none",{"count":538,"type":22},"This trial aims at collecting standardized data concerning the early neurological clinical recovery of patients, 3 months after endovascular treatment of an acute ischemic stroke.\n\nAlthough this outcome is a major issue of patients' prognosis, it is rarely collected at this stage of their follow-up.",[31],"2026-01-21",{"date":618,"type":38},"2026-01-22",{"date":620,"type":38},"2015-11-12",{"date":622,"type":22},"2031-05-12",{"name":624,"class":625},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":631,"acronym":632,"eligibilityCriteria":633,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":634,"enrollmentInfo":635,"targetDuration":4,"studyType":23,"phases":637,"briefSummary":638,"conditions":639,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":46},"100559821","efficacy-of-a-telehealth-delivered-group-lifestyle-balance-for-people-post-stroke-tglb-cva-100559821","NCT06569121","Efficacy of a Telehealth Delivered Group Lifestyle Balance for People Post Stroke (tGLB-CVA)","Efficacy of an Evidence-based Telehealth-delivered Weight-loss Intervention to Enhance Access and Reach Underserved Groups After Stroke","tGLB-CVA","Inclusion Criteria:\n\n* Body Mass Index ≥25\n* All types of stroke\n* Able to Participate in Physical Activity\n* ≥12 months post first stroke\n* Have internet, phone, or computer access, or be willing to use one provided by the study team\n\nExclusion Criteria:\n\n* Contraindications for physical activity\n* Low Cognitive Function\n* Residing in hospital, acute rehab, skilled nursing facility\n* Not fluent in the English language\n* Pre-existing eating disorder\n* Pregnancy","85 Years",{"count":636,"type":22},94,[25],"Investigators will conduct a randomized controlled trial (RCT) to assess intervention efficacy of telehealth delivery of the GLB-CVA (tGLB-CVA) compared to a 6-month wait-list control (WLC) in partnership with a diverse group of patient partners and peer mentors.",[31,64,640,641,642],"Stroke, Cardiovascular","Stroke (CVA) or TIA","Stroke\u002FBrain Attack","2026-01-19",{"date":616,"type":38},{"date":646,"type":38},"2024-12-07",{"date":648,"type":22},"2029-12-31",{"name":650,"class":45},"Baylor Research Institute"]